Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1038915-73-9
2. Mk-4827 Tosylate
3. Mk-4827 (tosylate)
4. Mk-4827-tosylate
5. Niraparib (tosylate)
6. Mk 4827 Tosylate
7. Niraparib (mk-4827) Tosylate
8. (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide 4-methylbenzenesulfonate
9. 75ke12ay9u
10. Mk-4827(niraparib) Tosylate
11. 2h-indazole-7-carboxamide, 2-(4-(3s)-3-piperidinylphenyl)-, 4-methylbenzenesulfonate (1:1)
12. Unii-75ke12ay9u
13. Niraparib Tosylate Monohyrate
14. Niraparib(mk-4827) Tosylate
15. Schembl20522624
16. Dtxsid801026487
17. Hy-10619b
18. Mfcd28167748
19. S7625
20. Ccg-269634
21. Niraparib Tosylate [orange Book]
22. Ac-30383
23. As-56981
24. A11848
25. A909268
26. Q27266392
27. (3s)-3-[4-[7-(aminocarbonyl)-2h-indazol-2-yl]phenyl]piperidine Tosylate
28. (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide 4-?methylbenzenesulfona?te
29. 4-methylbenzenesulfonic Acid;2-[4-[(3s)-piperidin-3-yl]phenyl]indazole-7-carboxamide
30. 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; 4-methylbenzene-1-sulfonic Acid
| Molecular Weight | 492.6 g/mol |
|---|---|
| Molecular Formula | C26H28N4O4S |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 492.18312656 g/mol |
| Monoisotopic Mass | 492.18312656 g/mol |
| Topological Polar Surface Area | 136 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 655 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41455
Submission : 2025-03-27
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Lee Fine Chem: Advancing Innovation and Quality in Intermediates, APIs, and Dosage Forms for Superior Pharmaceutical Solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41529
Submission : 2025-03-17
Status : Active
Type : II





FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Company : Janssen Biotech
Niraparib/Abiraterone
Drug Cost (USD) : 566,563
Year : 2023
Prescribers : 16
Prescriptions : 31

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Glaxosmithkline
Niraparib Tosylate
Drug Cost (USD) : 161,500,239
Year : 2023
Prescribers : 1886
Prescriptions : 10023

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Glaxosmithkline
Niraparib Tosylate
Drug Cost (USD) : 154,728,383
Year : 2022
Prescribers : 2211
Prescriptions : 11360

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Glaxosmithkline
Niraparib Tosylate
Drug Cost (USD) : 152,013,598
Year : 2021
Prescribers : 2662
Prescriptions : 11565

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Tesaro, Inc.
Niraparib Tosylate
Drug Cost (USD) : 364,669
Year : 2021
Prescribers : 15
Prescriptions : 41

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Tesaro, Inc.
Niraparib Tosylate
Drug Cost (USD) : 140,466,403
Year : 2020
Prescribers : 2766
Prescriptions : 10681

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Tesaro, Inc.
Niraparib Tosylate
Drug Cost (USD) : 95,099,948
Year : 2019
Prescribers : 1773
Prescriptions : 7528

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Tesaro, Inc.
Niraparib Tosylate
Drug Cost (USD) : 68,458,312
Year : 2018
Prescribers : 1451
Prescriptions : 5736

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
29 Sep 2022
Reply
16 Feb 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
75
PharmaCompass offers a list of Niraparib Tosylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Niraparib Tosylate manufacturer or Niraparib Tosylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Niraparib Tosylate manufacturer or Niraparib Tosylate supplier.
PharmaCompass also assists you with knowing the Niraparib Tosylate API Price utilized in the formulation of products. Niraparib Tosylate API Price is not always fixed or binding as the Niraparib Tosylate Price is obtained through a variety of data sources. The Niraparib Tosylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Niraparib Tosylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Niraparib Tosylate, including repackagers and relabelers. The FDA regulates Niraparib Tosylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Niraparib Tosylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Niraparib Tosylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Niraparib Tosylate supplier is an individual or a company that provides Niraparib Tosylate active pharmaceutical ingredient (API) or Niraparib Tosylate finished formulations upon request. The Niraparib Tosylate suppliers may include Niraparib Tosylate API manufacturers, exporters, distributors and traders.
click here to find a list of Niraparib Tosylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Niraparib Tosylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Niraparib Tosylate active pharmaceutical ingredient (API) in detail. Different forms of Niraparib Tosylate DMFs exist exist since differing nations have different regulations, such as Niraparib Tosylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Niraparib Tosylate DMF submitted to regulatory agencies in the US is known as a USDMF. Niraparib Tosylate USDMF includes data on Niraparib Tosylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Niraparib Tosylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Niraparib Tosylate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Niraparib Tosylate Drug Master File in Korea (Niraparib Tosylate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Niraparib Tosylate. The MFDS reviews the Niraparib Tosylate KDMF as part of the drug registration process and uses the information provided in the Niraparib Tosylate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Niraparib Tosylate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Niraparib Tosylate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Niraparib Tosylate suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Niraparib Tosylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Niraparib Tosylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Niraparib Tosylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Niraparib Tosylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Niraparib Tosylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Niraparib Tosylate suppliers with NDC on PharmaCompass.
Niraparib Tosylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Niraparib Tosylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Niraparib Tosylate GMP manufacturer or Niraparib Tosylate GMP API supplier for your needs.
A Niraparib Tosylate CoA (Certificate of Analysis) is a formal document that attests to Niraparib Tosylate's compliance with Niraparib Tosylate specifications and serves as a tool for batch-level quality control.
Niraparib Tosylate CoA mostly includes findings from lab analyses of a specific batch. For each Niraparib Tosylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Niraparib Tosylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Niraparib Tosylate EP), Niraparib Tosylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Niraparib Tosylate USP).